Summary
Many anticancer drugs require oxygen to be cytotoxic or are selectively cytotoxic toward cells under oxygenated conditions. The effects of the dilute perfluorochemical emuolsion Fluosol with a wide variety of chemotherapeutic agents have been explored; however, it has not been possbile to determine the optimal level of circulating perfluorochemical emulsion with anticancer drugs because the volume of Fluosol that may be administered is limiting. Using a new concentrated perfluorochemical emulsion, a wide range of perfluorochemical doses has been examined in combination with melphalan, cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in the FSaIIC fibrosarcoma. When the perfluorochemical emulsion was administered by injection i.v. just prior to the injection of melphalan (10 mg/kg), cyclophosphamide (150 mg/kg) or BCNU (50 mg/kg), the greatest tumor growth delays were obtained with dosage levels between 4 g and 12 g of the perfluorochemical perfluorooctyl bromide/kg. With each drug the greatest tumor growth delays were obtained when the drug was prepared in the emulsion and the combination injected i. v. In each case, each dose of drug was followed by 6 h of breathing carbogen. The addition of the perfluorochemical emulsion/carbogen breathing to treatment with melphalan, BCNU or cyclophosphamide resulted in significant increases in the killing of tumor cells by these drugs without a concomitant increase in toxicity to bone marrow granulocyte/macrophagecolony-forming units. In each case, preparing the drug in the perfluorochemical emulsion was most effective. These results indicate that clinical trial of this perfluorochemical emulsion/carbogen breathing in combination with cancer chemotherapy may be warranted.
Similar content being viewed by others
Abbreviations
- BCNU:
-
1,3-bis(2-chloroethyl)-1-nitrosourea
- CFUGM:
-
granulocyte/macrophage-colony-forming units
References
Adams GE (1990) The clinical relevance of tumor hypoxia. Eur J Cancer 265:420–421
Fowler JF (1987) Chemical modifiers of radiosensitivity — theory and reality: a review. Int J Radiat Oncol Biol Phys 11:665–677
Garewal H, Skarin A, Kessler J, Smith R, Hedberg J (1989) Fluosol/oxygen in combination with cyclophosphamide in advanced non-small cell lung carcinoma (NSCLC): phase I results. Proc Am Assoc Cancer Res 30:271
Groebe K, Vaupel P (1988) Evaluation of oxygen diffusion distances in human breast cancer xenografts using tumor-specific in vivo data: role of various mechanisms in the development of tumor hypoxia. Int J Radiat Oncol Biol Phys 15:691–697
Gruber M, Prados M, Russel C, Hochberg F, Cook P, Weissman D, Evans R, Burton G, Allen D, Brannon R (1990) Phase I/II study of Fluosol/O2 in combination with BCNU in malignant glioma. Proc Am Assoc Cancer Res 31:190
Herman TS, Teicher BA, Dewhirst M, Zimmermann D (1990a) Rate of infusion: an important factor in circulatory effects of perfluorochemical emulsions (PERFFLUBRONES). Int J Radiat Oncol Biol Phys 1951:136
Herman TS, Teicher BA, Holden SA, Pfeffer MR, Jones SM (1990b) Addition of 2-nitroimidazole radiosensitizers to trimodality therapy (cis-ciamminedichloroplatinum II/hyperthermia/radiation) in the murine FSaIIC fibrosarcoma. Cancer Res 50:2734–2740
Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P (1989) Blood flow, metabolism, cellular microenvironment and growth rate of human tumor xenografts. Cancer Res 49:3759–3764
Kallinowski F, Zander R, Höeckel M, Vaupel P (1990) Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys 19:953–961
Kennedy KA, Teicher BA, Rockwell SC, Sartorelli AC (1980) The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 29:1–8
Kim GE, Song CW (1989) The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo. Cancer Chemother Pharmacol 25:99–102
Meyers F, Alberts D, Spaulding M, Garewal H, Flam M, Allen D (1989) Phase I/II study of Fluosol/oxygen in combination with weekly 5-fluorouracil (5FU) in metastatic colorectal carcinoma. Proc Am Assoc Cancer Res 30:256
Rice L, Urano M, Suit HD (1980) The radiosensitivity of a murine fibrosarcoma as measured by three cell survival assays. Br J Cancer 41:240–245
Riess JG (1984) Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artif Organs 8:44–56
Riess JG, LeBlanc M (1982) Solubility and transport in perfluorochemicals relevant to blood substitution and other biomedical applications. Pure Appl Chem 54:2383–2406
Sartorelli AC (1988) Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 48:775–778
Schabel FM Jr, Griswold DP Jr., Corbett TH, Laster WR Jr, Mayo JG, Lloyd HH (1979) Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solit tumors of man. Methods Cancer Res 17:3–51
Teicher BA, Holden SA (1987) A survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents. Cancer Treat Rep 71:173–177
Teicher BA, Rose CM (1984) Perfluorochemical emulsion can increase tumor radiosensitivity. Science 223:934–936
Teicher BA, Sartorelli AC (1981) Selective attack of hypoxic tumor cells. In: Fidler IJ, White RJ (eds) Design of models for screening of therapeutic agents for cancer. Van Nostrund, New York, pp 19–37
Teicher BA, Lazo JS, Sartorelli AC (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73–81
Teicher BA, Holden SA, Rose CM (1985) Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing. Int J Cancer 36:585–589
Teicher BA, Holden SA, Rose CM (1986a) Effect of Fluosol-DA/O2 on tumor cell and bone marrow cytotoxicity of nitrosoureas in mice bearing FSaII fibrosarcoma. Int J Cancer 38:285–288
Teicher BA, Lazo JS, Merrill WW, Filderman AE, Rose CM (1986b) Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin. Cancer Chemother Pharmacol 18:213–218
Teicher BA, Crawford JM, Holden SA, Cathcart KNS (1987a) Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Res 47:5036–5041
Teicher BA, Holden SA, Jacobs JL (1987b) Approaches to defining the mechanism of Fluosol-DA 20%/carbogen enhancement of melphalan antitumor activity. Cancer Res 47:513–518
Teicher BA, Herman TS, Holden SA, Cathcart KNS (1988a) The effect of Fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo. Cancer Chemother Pharmacol 21:286–291
Teicher BA, Herman TS, Hold CM (1988b) Effect of Fluosol-DA on the response of intracranial 9L tumors to x-rays and BCNU. Int J Radiat Oncol Biol Phys 15:1187–1192
Teicher BA, Holden SA, Cathcart KNS, Herman TS (1988c) Effect of various oxygenation conditions and Fluosol-DA on the cytotoxicity and antitumor activity of bleomycin. J Natl Cancer Inst 80:599–603
Teicher BA, Holden SA, Crawford JM (1988d) Effects of Fluosol-DA and oxygen breathin on Adriamycin antitumor activity and cardiac toxicity in mice. Cancer 61:2196–2201
Teicher BA, McIntosh-Lowe NL, Rose CM (1988e) Effect of various oxygenation conditions and Fluosol-DA on cancer chemotherapeutic agents. Biomater Art Cells Art Organs 16:533–546
Teicher BA, Hermann TS, Jones SM (1989a) Optimization of perfluorochemical levels with radiation therapy in mice. Cancer Res 49:2693–2697
Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Alvarez Sotomayor E, Jones SM, Frei E III (1989b) Evidence for enzymatic activation and oxygen invovlement in cytotoxicity and antitumour activity ofN, N', N"-triethylenethiophosphoramide. Cancer Res 49:4996–5001
Teicher BA, Holden SA, Al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cencer Res 50:3339–3344
Vaupel P (1990) Oxygenation of human tumors. Strahlenther Onkol 166:377–386
Vaupel P, Schlenger K, Knoop C, Höeckel M (1991) Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancer by computerized O2 tension measurements. Cancer Res 51:3316–3322
Author information
Authors and Affiliations
Additional information
This work was supported by a grant form Alliance Pharmaceutical Corporation, San Diego, Calif.
Rights and permissions
About this article
Cite this article
Teicher, B.A., Holden, S.A., Ara, G. et al. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents. J Cancer Res Clin Oncol 118, 509–514 (1992). https://doi.org/10.1007/BF01225265
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01225265